RHHBY - Roche Holding AG

Other OTC - Other OTC Delayed Price. Currency in USD
27.93
-0.02 (-0.07%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close27.95
Open28.16
Bid0.00 x 0
Ask0.00 x 0
Day's Range27.93 - 28.28
52 Week Range27.48 - 34.67
Volume4,455,142
Avg. Volume1,987,390
Market Cap192.109B
Beta0.53
PE Ratio (TTM)21.34
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.08 (3.90%)
Ex-Dividend Date2018-03-15
1y Target EstN/A
Trade prices are not sourced from all markets
  • The story of how Bill Gates's dad saved Starbucks
    Yahoo Finance Video9 days ago

    The story of how Bill Gates's dad saved Starbucks

    And who knew that Bill Gates dad saved the company in the 1980s?

  • Yahoo Finance Live: Market Movers - May 10th, 2018
    Yahoo Finance Video10 days ago

    Yahoo Finance Live: Market Movers - May 10th, 2018

    Yahoo Finance's LIVE stock market coverage and analysis.

  • Buffett's Berkshire Hathaway halftime show
    Yahoo Finance Video14 days ago

    Buffett's Berkshire Hathaway halftime show

    Yahoo Finance editor-in-chief Andy Serwer, Jen Rogers, Julia La Roche and Myles Udland host the halftime break show at Berkshire Hathaway's annual shareholder meeting in Omaha, Nebraska featuring Warren Buffett and Charlie Munger.

  • Exelixis Is Focused on Management of the Cabozantinib Franchise
    Market Realist2 days ago

    Exelixis Is Focused on Management of the Cabozantinib Franchise

    Exelixis (EXEL) is focused on the label expansion and life cycle management of the cabozantinib franchise in collaboration with Bristol-Myers Squibb (BMY) and Roche Holdings (RHHBY). The above diagram shows the rationale for studying cabozantinib in combination with immunotherapy in multiple cancer indications. Exelixis is currently evaluating the safety and preliminary activity, in terms of objective response rate and progression-free survival, of a combination of cabozantinib with nivolumab and a combination of cabozantinib with nivolumab and ipilimumab in advanced hepatocellular carcinoma (or HCC) indications in an ongoing Phase 2 trial.

  • Roche Tecentriq Combo Achieves Longer Overall Survival Rate
    Zacks3 days ago

    Roche Tecentriq Combo Achieves Longer Overall Survival Rate

    Roche's (RHHBY) immuno-oncology drug, Tecentriq, in combination with Avastin and chemotherapies leads to significantly longer overall survival rates in treatment-naive NSCLC patients.

  • Why Exelixis Stock Fell Last Week
    Market Realist3 days ago

    Why Exelixis Stock Fell Last Week

    On May 11, Exelixis’s (EXEL) closing price was $19.55, almost 12.9% lower than its closing price on May 4. This fall was mainly attributable to unfavorable results released from its Phase 3 IMblaze370 study comparing a combination regimen of Cotellic (cobimetinib) with Roche Holdings’ (RHHBY) Tecentriq (atezolizumab) compared to Bayer’s Stivarga in locally advanced or metastatic colorectal cancer indications. Exelixis and Roche Holdings’ investigational combination regimen failed to demonstrate a statistically significant improvement in the primary end point of overall survival compared to Stivarga in difficult-to-treat patients who had witnessed disease progression or had been unable to tolerate at least two chemotherapy treatments.

  • Reuters3 days ago

    Roche immunotherapy combination increases lung cancer survival-study

    Roche's immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tecentriq, according to interim results of a late stage trial released on Wednesday. The Phase III study involved 800 people with non-squamous non-small cell lung cancer (NSCLC) whose cancer had spread but who had not yet received chemotherapy.

  • The Wall Street Journal4 days ago

    [$$] No Harm in Reducing Use of Roche Drug for Breast Cancer, Study Says

    The study, funded by the U.K. National Institute for Health Research, was conducted on more than 4,000 women in the early stages of an aggressive type of breast cancer known as HER2-positive. Herceptin, which generated about $7 billion in global sales for Roche last year, has vastly improved treatment for HER2-positive breast cancer since it hit the market in 1998, particularly when used to prevent disease recurrence after breast surgery. In the U.S., the drug costs $76,700 for 12 months of treatment.

  • Study Finds More Isn't Better for Roche Breast Cancer Drug
    Bloomberg4 days ago

    Study Finds More Isn't Better for Roche Breast Cancer Drug

    For more than a decade, women with a dangerous form of breast cancer have relied on Roche Holding AG’s blockbuster drug Herceptin, taking the $76,700-a-year medicine for 12 months to fight off the disease. According to research released Wednesday, women taking Herceptin for six months were just as likely to be free of cancer four years later as those who used the drug for a year, the current standard of care recommended by the U.S. Food and Drug Administration and Roche. “Our field is maturing,” said Bruce Johnson, chief clinical research officer at the Dana-Farber Cancer Institute in Boston and president of the American Society of Clinical Oncology, or ASCO.

  • Reuters4 days ago

    Roche breast cancer drug treatment time can be halved - study

    Treating early stage breast cancer patients for just six months with Roche's Herceptin works as well as the current 12-month regimen, researchers who conducted a large clinical trial said on Wednesday. Herceptin, a biotech medicine that costs around $76,700 a year in the United States, generated 2017 worldwide sales of more than $7 billion for Roche. If a shorter treatment duration is widely adopted it could significantly reduce sales.

  • Roche's Actemra Gets FDA Nod for Subcutaneous Formulation
    Zacks5 days ago

    Roche's Actemra Gets FDA Nod for Subcutaneous Formulation

    FDA approves the subcutaneous formulation of Roche's (RHHBY) Actemra for the treatment of active polyarticular juvenile idiopathic arthritis in patients two years or older.

  • Merck Focuses on Multiple R&D Programs for Keytruda in 2018
    Market Realist9 days ago

    Merck Focuses on Multiple R&D Programs for Keytruda in 2018

    On April 15, Merck (MRK) in collaboration with the European Organisation for Research and Treatment of Cancer (or EORTC) announced positive results from the Phase 3 KEYNOTE-054 trial, which highlighted the efficacy of Keytruda as adjuvant therapy for high-risk stage III melanoma patients who have previously undergone surgery.

  • Pharma Stock Roundup: LLY to Buy Cancer Biotech, J&J, AZN, Roche Announce Updates
    Zacks9 days ago

    Pharma Stock Roundup: LLY to Buy Cancer Biotech, J&J, AZN, Roche Announce Updates

    Lilly signs deal to buy immuno-oncology biotech ARMO Biosciences for about $1.6 billion. J&J's Darzalex gains FDA approval in first-line setting.

  • Label Expansion May Boost Keytruda’s Revenue Prospects in 2018
    Market Realist9 days ago

    Label Expansion May Boost Keytruda’s Revenue Prospects in 2018

    Merck’s (MRK) Keytruda has managed to secure U.S. Food and Drug Administration (or FDA) approval in ten different indications across seven tumor types: melanoma, urothelial cancer, classical Hodgkin lymphoma, squamous cell carcinoma of head and neck, non-small cell lung cancer (or NSCLC), gastric cancer, and solid tumors that have microsatellite instability (or MSI) or DNA mismatch repair deficiency. The drug has already emerged as the leading immunotherapy in metastatic NSCLC, bladder cancer, and head and neck cancer indications.

  • Keytruda Continues to Be Major Growth Driver for Merck in 2018
    Market Realist9 days ago

    Keytruda Continues to Be Major Growth Driver for Merck in 2018

    In 1Q18, Merck’s (MRK) Keytruda reported global sales close to $1.5 billion, which is a year-over-year (or YoY) rise of around 151%. The rise was attributable to the highest number of new patient starts for Keytruda in the US as compared to other immunotherapy drugs such as Bristol-Myers Squibb’s (BMY) Opdivo and Roche Holdings’ (RHHBY) Tecentriq. The drug has established itself as a leading therapy for metastatic lung cancer in the US.

  • This Biotech Stock Crashed On Colon Cancer Flop With Roche
    Investor's Business Daily10 days ago

    This Biotech Stock Crashed On Colon Cancer Flop With Roche

    Exelixis stock tanked Thursday after a regimen using its drug and another from Roche failed in a late-stage study of hard-to-treat colon cancer patients.

  • Why Exelixis Dropped Today
    Motley Fool10 days ago

    Why Exelixis Dropped Today

    The company announced a disappointing clinical trial failure, which fortunately wasn't for its top-selling drug.

  • Inovio's (INO) Q1 Loss Wider than Expected, Shares Down
    Zacks10 days ago

    Inovio's (INO) Q1 Loss Wider than Expected, Shares Down

    Inovio (INO) reports wider-than-expected loss and revenues miss estimates in the first quarter of 2018.

  • How Did Regeneron’s Eylea, Kevzara, and Zaltrap Perform in 1Q18?
    Market Realist11 days ago

    How Did Regeneron’s Eylea, Kevzara, and Zaltrap Perform in 1Q18?

    In 1Q18, Eylea generated net global revenue of $1.6 billion compared to $1.3 billion in 1Q17, which reflected a ~20% rise on a YoY (year-over-year) basis.

  • Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q1
    Zacks11 days ago

    Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q1

    Epizyme (EPZM) betters loss estimates in Q1 and expects to file a new drug application to the FDA for its lead pipeline candidate tazemetostat in fourth-quarter 2018.

  • Prothena (PRTA) Q1 Loss Wider Than Expected, Sales Miss
    Zacks11 days ago

    Prothena (PRTA) Q1 Loss Wider Than Expected, Sales Miss

    Prothena's (PRTA) wider-than-expected loss in the first quarter was disappointing. Sales also missed estimates by a huge margin.

  • Is a Beat in Store for Epizyme (EPZM) This Earnings Season?
    Zacks12 days ago

    Is a Beat in Store for Epizyme (EPZM) This Earnings Season?

    Epizyme (EPZM) is expected to provide updates on pipeline candidates when it reports Q1 results on May 8.

  • Alimta: An Emerging Drug to Treat Lung Cancer
    Market Realist13 days ago

    Alimta: An Emerging Drug to Treat Lung Cancer

    On April 30, the FDA granted priority review status to the sBLA (supplemental biologics license application) seeking approval for the combination of Merck’s (MRK) Keytruda, Eli Lilly’s (LLY) Alimta, and platinum-based chemotherapy agents like carboplatin or cisplatin in first-line metastatic NSCLC (non-squamous non-small cell lung cancer) indication. The Prescription Drug User Fee Act’s date is September 23. The sBLA is based on data from the Phase 3 KEYNOTE-189 trial declared on April 16. ...

  • How Amgen’s Enbrel and Neulasta Performed in 1Q18
    Market Realist13 days ago

    How Amgen’s Enbrel and Neulasta Performed in 1Q18

    In 1Q18, Amgen’s (AMGN) Enbrel revenue fell 6% YoY (year-over-year) to $1.1 billion from $1.2 billion, primarily due to lower unit demand and selling prices. It grew ~22% QoQ (quarter-over-quarter). In US and international markets, Enbrel generated revenue of $1.05 billion and $55 million, respectively, compared with $1.1 billion and $63 million in 1Q17.

  • Reuters13 days ago

    Roche's Tecentriq combo wins fast FDA review in race to catch rivals

    Roche's immunotherapy combination that includes Tecentriq, Avastin and chemotherapy will get an accelerated review by U.S. regulators for use as an initial treatment of a common form of lung cancer, the Swiss drugmaker said on Monday. Roche expects a U.S. Food and Drug Administration decision by Sept. 5. It has already announced some results of clinical trials that showed the cocktail boosted survival benefit for patients with metastatic non-squamous non-small cell lung cancer (NSCLC) compared to older treatments.